Epigenomics AG (FRA:ECX) Long-Term Debt: €11.38 Mil (As of Dec. 2025)


FRA:ECX Epigenomics AG FRA:ECX
11 GF Score
Price €0.88
GF Value €0.09
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Long-Term Debt?

Epigenomics AG FRA:ECX -18.98% 11 Long-Term Debt is €11.38 Mil as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 11/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Epigenomics AG's Long-Term Debt for the quarter that ended in Dec. 2025 was €11.38 Mil.

Epigenomics AG's quarterly Long-Term Debt stayed the same from Dec. 2024 (€11.38 Mil) to Jun. 2025 (€11.38 Mil) but then declined from Jun. 2025 (€11.38 Mil) to Dec. 2025 (€11.38 Mil).

Epigenomics AG's annual Long-Term Debt declined from Dec. 2023 (€11.89 Mil) to Dec. 2024 (€11.38 Mil) and declined from Dec. 2024 (€11.38 Mil) to Dec. 2025 (€11.38 Mil).

Epigenomics AG  (FRA:ECX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Epigenomics AG Long-Term Debt Related Terms

Epigenomics AG Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Epigenomics AG's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG Long-Term Debt Chart

Epigenomics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 12.66 11.89 11.38 11.38

Epigenomics AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.89 11.42 11.38 11.38 11.38
FRA:ECX
11GF Score
Epigenomics AG FRA:ECX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €11.38 Mil mean?
Epigenomics AG (FRA:ECX) has a Long-Term Debt of €11.38 Mil as of Dec. 2025.
Is Epigenomics AG's Long-Term Debt too high?
Epigenomics AG's current Long-Term Debt is €11.38 Mil. Overall, Epigenomics AG has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Long-Term Debt compare to TMO and DHR?
Epigenomics AG's Long-Term Debt of €11.38 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Epigenomics AG's current Long-Term Debt is €11.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.88 — trading 872.2% above its estimated fair value. The current Long-Term Debt is €11.38 Mil. Epigenomics AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Long-Term Debt is €11.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Epigenomics AG (FRA:ECX) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €0.88 is trading 872.2% above its estimated GF Value™ of €0.09. GuruFocus considers Epigenomics AG to be Significantly Overvalued.

Key valuation signals for FRA:ECX:

  • Long-Term Debt: €11.38 Mil
  • GF Value™: €0.09 vs. price of €0.88 (872.2% above fair value)
  • GF Score™: 11/100 with 3 warning signs

No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
11GF Score

Get the complete analysis for FRA:ECX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€0.09
GF Value